200,000+ products from a single source!
sales@angenechem.com
Home > Fluorides > 101477-54-7
101477-54-7 | Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]-, hydrochloride (1:2)
CAS No: 101477-54-7 Catalog No: AG0004KV MDL No:MFCD01703867
Product Description
Catalog Number:
AG0004KV
Chemical Name:
Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]-, hydrochloride (1:2)
CAS Number:
101477-54-7
Molecular Formula:
C27H32Cl2F2N2O3
Molecular Weight:
541.4574
MDL Number:
MFCD01703867
IUPAC Name:
1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine;dihydrochloride
InChI:
InChI=1S/C27H30F2N2O3.2ClH/c1-32-24-13-8-21(26(33-2)27(24)34-3)18-30-14-16-31(17-15-30)25(19-4-9-22(28)10-5-19)20-6-11-23(29)12-7-20;;/h4-13,25H,14-18H2,1-3H3;2*1H
InChI Key:
LOGVKVSFYBBUAJ-UHFFFAOYSA-N
SMILES:
COc1c(ccc(c1OC)OC)CN1CCN(CC1)C(c1ccc(cc1)F)c1ccc(cc1)F.Cl.Cl
UNII:
3W473D5LIY
Properties
Complexity:
568
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
3
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
540.176g/mol
Formal Charge:
0
Heavy Atom Count:
36
Hydrogen Bond Acceptor Count:
7
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
541.461g/mol
Monoisotopic Mass:
540.176g/mol
Rotatable Bond Count:
8
Topological Polar Surface Area:
34.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Why are most phospholipidosis inducers also hERG blockers? | Archives of toxicology 20171201 |
| Changes in optic nerve head circulation in response to vasoactive agents: intereye comparison in monkeys with experimental unilateral glaucoma. | Investigative ophthalmology & visual science 20120822 |
| Neuroprotection by lomerizine, a prophylactic drug for migraine, against hydrogen peroxide-induced hippocampal neurotoxicity. | Molecular and cellular biochemistry 20111201 |
| Development of spontaneous neuropathy in NF-κBp50-deficient mice by calcineurin-signal involving impaired NF-κB activation. | Molecular vision 20110101 |
| Interaction of CJZ3, a lomerizine derivative, with ATPase activity of human P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. | Die Pharmazie 20100701 |
| Lomerizine, a Ca2+ channel blocker, protects against neuronal degeneration within the visual center of the brain after retinal damage in mice. | CNS neuroscience & therapeutics 20100401 |
| Limited restoration of visual function after partial optic nerve injury; a time course study using the calcium channel blocker lomerizine. | Brain research bulletin 20100316 |
| A case of ocular hypertension complicated by SUNCT syndrome. | Annals of ophthalmology (Skokie, Ill.) 20100101 |
| Secondary retinal ganglion cell death and the neuroprotective effects of the calcium channel blocker lomerizine. | Investigative ophthalmology & visual science 20091101 |
| Inhibitory effect of lomerizine, a prophylactic drug for migraines, on serotonin-induced contraction of the basilar artery. | Journal of pharmacological sciences 20091001 |
| [Calcium antagonists in the prophylactic treatment of migraine]. | Brain and nerve = Shinkei kenkyu no shinpo 20091001 |
| Secondary degeneration of the optic nerve following partial transection: the benefits of lomerizine. | Experimental neurology 20090301 |
| Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine. | Clinical neuropharmacology 20090101 |
| [CADASIL]. | Brain and nerve = Shinkei kenkyu no shinpo 20081101 |
| Goshuyuto, a traditional Japanese medicine for migraine, inhibits platelet aggregation in guinea-pig whole blood. | Journal of pharmacological sciences 20080901 |
| Atypical depression as a premonitory symptom of migraine managed by an oral contraceptive. | Psychiatry and clinical neurosciences 20080601 |
| Migraine-associated vertigo: clinical characteristics of Japanese patients and effect of lomerizine, a calcium channel antagonist. | Acta oto-laryngologica. Supplementum 20071201 |
| CJZ3, a lomerizine derivative, modulates P-glycoprotein function in rat brain microvessel endothelial cells. | Acta pharmacologica Sinica 20060401 |
| A new calcium channel antagonist, lomerizine, alleviates secondary retinal ganglion cell death after optic nerve injury in the rat. | Current eye research 20060301 |
| [Reversal of multidrug resistance by lomerizine in K562/ADM cells]. | Yao xue xue bao = Acta pharmaceutica Sinica 20040501 |
| Clinical potential of lomerizine, a Ca2+ channel blocker as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. | Cardiovascular drug reviews 20040101 |
| [Effects of changes in conformation and configuration of N-containing compounds on NMR spactra]. | Yao xue xue bao = Acta pharmaceutica Sinica 20031201 |
| Effects of lomerizine, a calcium channel antagonist, on retinal and optic nerve head circulation in rabbits and humans. | Investigative ophthalmology & visual science 20031101 |
| Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine. | Biological & pharmaceutical bulletin 20010501 |
| Effects of lomerizine, a novel Ca2+ channel blocker, on the normal and endothelin-1-disturbed circulation in the optic nerve head of rabbits. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20010401 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.